MeiraGTx gains as gene therapy shows promise in Parkinson’s

seekingalpha10-15

koto_feja MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising trial results for its gene therapy candidate AAV-GAD in Parkinson'...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475060135?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1434534146/image_1434534146.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-15 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475060135","market":"sh","top_or_hot":-1,"title":"MeiraGTx gains as gene therapy shows promise in Parkinson’s","media":"seekingalpha","content":"<div>\n<p>koto_feja MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising trial results for its gene therapy candidate AAV-GAD in Parkinson'...</p>\n\n<a href=\"https://seekingalpha.com/news/4159679-meiragtx-stock-gains-parkinsons-drug-data\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MeiraGTx gains as gene therapy shows promise in Parkinson’s</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeiraGTx gains as gene therapy shows promise in Parkinson’s\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 20:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4159679-meiragtx-stock-gains-parkinsons-drug-data><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>koto_feja MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising trial results for its gene therapy candidate AAV-GAD in Parkinson'...</p>\n\n<a href=\"https://seekingalpha.com/news/4159679-meiragtx-stock-gains-parkinsons-drug-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SQQQ","symbol_name":"纳指三倍做空ETF","start_time":0,"source_url":"https://seekingalpha.com/news/4159679-meiragtx-stock-gains-parkinsons-drug-data","article_id":"2475060135","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1434534146/image_1434534146.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475060135","pubTimestamp":1728995252,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"koto_feja MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising trial results for its gene therapy candidate AAV-GAD in Parkinson's disease, the second most common neurodegenerative disease in the U.S. Citing topline data from a","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SQQQ":"纳指三倍做空ETF","BK4139":"生物科技","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","MGTX":"Meiragtx Holdings Plc","QID":"纳指两倍做空ETF"},"translate_title":"基因疗法在帕金森病中显示出前景，MeiraGTx收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGTX":0.9,".IXIC":0.69,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"koto_feja MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising trial results for its gene therapy candidate AAV-GAD in Parkinson's disease, the second most common neurodegenerative disease in the U.S. Citing topline data from a","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475060135"}